Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients

被引:206
作者
Ferrandina, G
Zannoni, GF
Martinelli, E
Paglia, A
Gallotta, V
Mozzetti, S
Scambia, G
Ferlini, C
机构
[1] Catholic Univ, Dept Oncol, Campobasso, Italy
[2] Catholic Univ, Inst Human Pathol, Rome, Italy
[3] Catholic Univ, Gynecol Oncol Unit, Rome, Italy
关键词
D O I
10.1158/1078-0432.CCR-05-2715
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Overexpression of beta III tubulin has been involved in paclitaxel resistance in several experimental models. We investigated the role of beta III tubulin as predictor of clinical outcome in ovarian cancer patients given platinum/paclitaxel treatment. We also investigated whether beta III tubulin expression could be modified after the selective pressure represented by chemotherapy in vivo. Experimental Design: The study was designed to include a series of consecutive ovarian cancer patients with unresectable disease at time of first surgery, who underwent interval debulking surgery with pathologic assessment of response to treatment with platinum/ paclitaxel chemotherapy. Immunostaining was done on formalin-fixed, paraffin-embedded tissue sections from pretreatment and posttreatment tissue biopsies by using the polyclonal rabbit anti-class III beta-tubulin antibody. Results: beta III Tubulin immunoreaction was observed in 51 of 62 (82.2%) cases. beta III Tubulin positivity was neither associated with clinicopathologic variables nor with pathologic response to chemotherapy. Significantly lower percentages of beta III tubulin positivity were observed in posttreatment (range, 5-80%; median, 20%) versus pretreatment (range 10-100%; median, 40%) tissue biopsies (P = 0.0011). Cases with high beta III tubulin expression showed a worse overall survival with respect to cases with low beta III tubulin expression (median overall survival, 25 versus 46 months; P = 0.002). Multivariate analysis showed that high content of beta III tubulin remains independently associated with a worse prognosis. Conclusions: Assessment of beta III tubulin could be useful to identify poor prognosis ovarian cancer patients candidates to more aggressive and/or targeted therapy.
引用
收藏
页码:2774 / 2779
页数:6
相关论文
共 35 条
[1]  
[Anonymous], PRINCIPLES PRACTICE
[2]  
Bernard-Marty Chantal, 2002, Clin Breast Cancer, V3, P341, DOI 10.3816/CBC.2002.n.037
[3]   Hypoxia:: the tumor's gateway to progression along the angiogenic pathway [J].
Brahimi-Horn, C ;
Berra, E ;
Pouysségur, J .
TRENDS IN CELL BIOLOGY, 2001, 11 (11) :S32-S36
[4]   Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome [J].
Brizel, DM ;
Dodge, RK ;
Clough, RW ;
Dewhirst, MW .
RADIOTHERAPY AND ONCOLOGY, 1999, 53 (02) :113-117
[5]   Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines [J].
Chang, JT ;
Chang, GC ;
Ko, JL ;
Liao, HY ;
Liu, HJ ;
Chen, CC ;
Su, JM ;
Lee, H ;
Sheu, GT .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (02) :317-325
[6]   Critique of surgical cytoreduction in advanced ovarian cancer [J].
Covens, AL .
GYNECOLOGIC ONCOLOGY, 2000, 78 (03) :269-274
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes [J].
Derry, WB ;
Wilson, L ;
Khan, IA ;
Luduena, RF ;
Jordan, MA .
BIOCHEMISTRY, 1997, 36 (12) :3554-3562
[9]   Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients [J].
Fanfani, F ;
Ferrandina, G ;
Corrado, G ;
Fagotti, A ;
Zakut, HV ;
Mancuso, S ;
Scambia, G .
ONCOLOGY, 2003, 65 (04) :316-322
[10]   The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance [J].
Ferlini, C ;
Raspaglio, G ;
Mozzetti, S ;
Cicchillitti, L ;
Filippetti, F ;
Gallo, D ;
Fattorusso, C ;
Campriani, G ;
Scambia, G .
CANCER RESEARCH, 2005, 65 (06) :2397-2405